Angiodynamics To Realize Independence From E-Z-Em Through IPO
This article was originally published in The Gray Sheet
Executive Summary
Angiodynamics asserts that its focus on peripheral vascular disease (PVD) and its broad product line will enable the firm to hold its own against larger competitors once it goes public